Mark Massaro
Stock Analyst at BTIG
(4.30)
# 381
Out of 5,148 analysts
186
Total ratings
50.91%
Success rate
17.2%
Average return
Main Sectors:
Stocks Rated by Mark Massaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Buy | $45 → $38 | $20.66 | +83.93% | 1 | Feb 27, 2026 | |
| CDNA CareDx | Maintains: Buy | $25 → $26 | $18.75 | +38.70% | 6 | Feb 26, 2026 | |
| TEM Tempus AI | Maintains: Buy | $105 → $90 | $53.31 | +68.82% | 7 | Feb 25, 2026 | |
| WGS GeneDx Holdings | Maintains: Buy | $200 → $170 | $74.20 | +129.11% | 8 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $140 → $145 | $92.23 | +57.22% | 8 | Feb 20, 2026 | |
| XGN Exagen | Maintains: Buy | $15 → $10 | $3.55 | +181.69% | 6 | Feb 17, 2026 | |
| PSNL Personalis | Maintains: Buy | $12 → $13 | $9.06 | +43.49% | 5 | Feb 11, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Buy | $21 → $22 | $16.12 | +36.48% | 8 | Feb 6, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Buy | $830 → $800 | $636.70 | +25.65% | 3 | Feb 3, 2026 | |
| MDXH MDxHealth | Reiterates: Buy | $7 | $3.37 | +107.72% | 10 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $50 | $27.99 | +78.64% | 6 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $78.65 | +103.43% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $260 | $200.17 | +29.89% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $128.96 | +24.07% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $103.35 | - | 20 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $4.62 | +51.52% | 3 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $2.5 | $1.45 | +72.41% | 4 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $6 → $9 | $7.05 | +27.66% | 7 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.79 | - | 4 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 8 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $21 | $9.50 | +121.05% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.38 | - | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.53 | - | 1 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $350 → $300 | $132.89 | +125.75% | 6 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $52 → $50 | $75.45 | -33.73% | 9 | Nov 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $112 | $210.25 | -46.73% | 10 | Jul 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $155 → $165 | $286.47 | -42.40% | 10 | May 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $22.60 | +253.98% | 9 | Sep 10, 2018 |
Caris Life Sciences
Feb 27, 2026
Maintains: Buy
Price Target: $45 → $38
Current: $20.66
Upside: +83.93%
CareDx
Feb 26, 2026
Maintains: Buy
Price Target: $25 → $26
Current: $18.75
Upside: +38.70%
Tempus AI
Feb 25, 2026
Maintains: Buy
Price Target: $105 → $90
Current: $53.31
Upside: +68.82%
GeneDx Holdings
Feb 24, 2026
Maintains: Buy
Price Target: $200 → $170
Current: $74.20
Upside: +129.11%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $140 → $145
Current: $92.23
Upside: +57.22%
Exagen
Feb 17, 2026
Maintains: Buy
Price Target: $15 → $10
Current: $3.55
Upside: +181.69%
Personalis
Feb 11, 2026
Maintains: Buy
Price Target: $12 → $13
Current: $9.06
Upside: +43.49%
Adaptive Biotechnologies
Feb 6, 2026
Maintains: Buy
Price Target: $21 → $22
Current: $16.12
Upside: +36.48%
IDEXX Laboratories
Feb 3, 2026
Maintains: Buy
Price Target: $830 → $800
Current: $636.70
Upside: +25.65%
MDxHealth
Dec 23, 2025
Reiterates: Buy
Price Target: $7
Current: $3.37
Upside: +107.72%
Dec 12, 2025
Maintains: Buy
Price Target: $38 → $50
Current: $27.99
Upside: +78.64%
Dec 10, 2025
Reiterates: Buy
Price Target: $160
Current: $78.65
Upside: +103.43%
Dec 5, 2025
Maintains: Buy
Price Target: $230 → $260
Current: $200.17
Upside: +29.89%
Dec 3, 2025
Reiterates: Buy
Price Target: $160
Current: $128.96
Upside: +24.07%
Nov 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $103.35
Upside: -
Nov 10, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $4.62
Upside: +51.52%
Sep 10, 2025
Reiterates: Buy
Price Target: $2.5
Current: $1.45
Upside: +72.41%
Aug 25, 2025
Maintains: Sell
Price Target: $6 → $9
Current: $7.05
Upside: +27.66%
Aug 11, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.79
Upside: -
Sep 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
May 2, 2024
Maintains: Buy
Price Target: $23 → $21
Current: $9.50
Upside: +121.05%
Mar 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.38
Upside: -
Jan 20, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.53
Upside: -
Sep 22, 2020
Maintains: Hold
Price Target: $350 → $300
Current: $132.89
Upside: +125.75%
Nov 11, 2019
Maintains: Hold
Price Target: $52 → $50
Current: $75.45
Upside: -33.73%
Jul 24, 2019
Maintains: Buy
Price Target: $108 → $112
Current: $210.25
Upside: -46.73%
May 2, 2019
Maintains: Hold
Price Target: $155 → $165
Current: $286.47
Upside: -42.40%
Sep 10, 2018
Maintains: Buy
Price Target: $78 → $80
Current: $22.60
Upside: +253.98%